<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dog and cat bites: Intravenous antibiotic regimens for empiric treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dog and cat bites: Intravenous antibiotic regimens for empiric treatment</h1>
<div class="graphic"><div class="figure"><div class="ttl">Dog and cat bites: Intravenous antibiotic regimens for empiric treatment</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="25%"></colgroup><colgroup width="50%"></colgroup> <tbody> <tr> <td class="subtitle1">Antibiotic</td> <td class="subtitle1">Adults</td> <td class="subtitle1">Children and infants &gt;28 days old<sup>[1]</sup></td> </tr> <tr> <td class="subtitle2_left" colspan="3">Preferred regimens include:</td> </tr> <tr> <td class="indent1" colspan="3">Monotherapy with a beta-lactam/beta-lactamase inhibitor, such as one of the following:</td> </tr> <tr> <td class="indent2">Ampicillin-sulbactam</td> <td>3 g every 6 hours</td> <td>50 mg/kg (based on ampicillin component; maximum 2 g per dose) every 6 hours</td> </tr> <tr> <td class="indent2">Piperacillin-tazobactam</td> <td>3.375 g every 6 to 8 hours</td> <td>100 mg/kg (based on piperacillin component; maximum 3 g per dose) every 8 hours</td> </tr> <tr> <td class="indent1" colspan="3"><strong>or</strong></td> </tr> <tr> <td class="indent1" colspan="3">A third-generation cephalosporin, such as:</td> </tr> <tr> <td class="indent2">Ceftriaxone</td> <td>1 g every 12 hours or 2 g every 24 hours</td> <td>50 to 75 mg/kg every 24 hours or 50 mg/kg every 12 hours (maximum 1 g per dose)</td> </tr> <tr> <td class="indent2" colspan="3"><strong>plus</strong></td> </tr> <tr> <td class="indent2" colspan="3">One of the following agents with anaerobic activity:</td> </tr> <tr> <td class="indent3">Metronidazole</td> <td>500 mg every 8 hours</td> <td>10 mg/kg every 8 hours (maximum 500 mg per dose)</td> </tr> <tr> <td class="indent3">Clindamycin*<sup>¶</sup></td> <td>600 mg every 6 to 8 hours</td> <td>10 to 13 mg/kg every 8 hours (maximum 900 mg per dose)</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Alternative regimens include:</td> </tr> <tr> <td class="indent1" colspan="3">A fluoroquinolone, such as one of the following:</td> </tr> <tr> <td class="indent2">Ciprofloxacin<sup>Δ</sup></td> <td>400 mg every 12 hours</td> <td>Use with caution in children &lt;18 years of age:<sup>◊</sup> <ul class="decimal_heading"> <li>10 to 15 mg/kg twice daily (maximum 400 mg per dose)</li> </ul> </td> </tr> <tr> <td class="indent2">Levofloxacin<sup>Δ</sup></td> <td>750 mg daily</td> <td>Use with caution in children &lt;18 years of age:<sup>◊</sup> <ul class="decimal_heading"> <li>≥6 months old and &lt;50 kg: 8 to 10 mg/kg every 12 hours (maximum 375 mg per dose)</li> <li>&gt;50 kg: 500 mg every 24 hours (maximum 750 mg per day)</li> </ul> </td> </tr> <tr> <td class="indent2" colspan="3"><strong>plus</strong></td> </tr> <tr> <td class="indent2" colspan="3">One of the following agents with anaerobic activity:</td> </tr> <tr> <td class="indent3">Metronidazole</td> <td>500 mg every 8 hours</td> <td>10 mg/kg every 8 hours (maximum 500 mg per dose)</td> </tr> <tr> <td class="indent3">Clindamycin*<sup>¶</sup></td> <td>600 mg every 6 to 8 hours</td> <td>10 to 13 mg/kg every 8 hours (maximum 900 mg per dose)</td> </tr> <tr> <td class="indent1" colspan="3"><strong>or</strong></td> </tr> <tr> <td class="indent1" colspan="3">Monotherapy with a carbapenem, such as one of the following:</td> </tr> <tr> <td class="indent2">Imipenem-cilastatin</td> <td>500 mg every 6 hours</td> <td>15 to 25 mg/kg every 6 hours (maximum 500 mg per dose)</td> </tr> <tr> <td class="indent2">Meropenem</td> <td>1 g every 8 hours</td> <td>20 mg/kg every 8 hours (maximum 1 g per dose)</td> </tr> <tr> <td class="indent2">Ertapenem</td> <td>1 g daily</td> <td> <p>Children &lt;13 years old: 15 mg/kg every 12 hours (maximum 500 mg per dose)</p> Children ≥13 years old: 1 g daily</td> </tr> <tr> <td class="indent1" colspan="3"><strong>or</strong></td> </tr> <tr> <td class="indent1" colspan="3">Monotherapy with a fluoroquinolone:</td> </tr> <tr> <td class="indent2">Moxifloxacin<sup>Δ</sup><sup>§</sup></td> <td>400 mg daily</td> <td>Not recommended; insufficient experience</td> </tr> </tbody></table></div><div class="graphic_lgnd">The doses recommended above are intended for patients with normal renal function; the doses of some of these agents must be adjusted in patients with renal insufficiency. When a range of doses is given, the higher dose is used for more severe infections. We add coverage for MRSA (eg, with intravenous vancomycin) in patients who have severe illness, abscess, MRSA risk factors, or gram-positive cocci in clusters on Gram stain of the wound. Refer to the UpToDate topics on soft tissue infections due to dog and cat bites and MRSA treatment for recommendations.</div><div class="graphic_footnotes"><p>MRSA: methicillin-resistant <em>Staphylococcus aureus</em>.</p>
<p>* We generally avoid clindamycin, if possible, due to risk for Clostridium difficile infection and the possibility of streptococcal and staphylococcal resistance (refer to UpToDate content for details).</p>
<p>¶ Clindamycin may also be active against MRSA; if it is used for MRSA, confirm susceptibility.</p>
<p>Δ In general, fluoroquinolones should be reserved for when other regimens are not options. If used, patients should be advised about the uncommon but potentially serious musculoskeletal, cardiac, and neurologic adverse effects associated with fluoroquinolones. Refer to UpToDate content for details.</p>
<p>◊ Use of fluoroquinolones in children should be limited to the treatment of infections for which no safe and effective alternative exists or in situations where oral therapy is a reasonable alternative to intravenous therapy with a different class of antibiotics.<sup>[1]</sup></p>
    
    § Moxifloxacin has good anaerobic activity and can be used as a monotherapy, but other options are preferable.<sup>[2]</sup></div><div class="graphic_reference">Data from:
    <ol>
<li>American Academy of Pediatrics. Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021.</li>
<li>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:147.</li>
</ol></div><div id="graphicVersion">Graphic 63280 Version 17.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
